青海春天(600381) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 84,499,399.27, representing a year-on-year increase of 49.96% primarily due to growth in beverage and Cordyceps sinensis business[5] - The net profit attributable to shareholders of the listed company was a loss of CNY 26,905,064.87, with basic and diluted earnings per share both at -0.0458 yuan[5] - The net profit for Q1 2024 was -25,962,451.61 RMB, an improvement from -27,835,471.27 RMB in Q1 2023, representing a decrease in net loss of approximately 6.3%[18] - Operating profit for Q1 2024 was -23,788,381.41 RMB, compared to -27,451,702.32 RMB in Q1 2023, indicating a reduction in operating loss of about 13.3%[18] - The total comprehensive loss for Q1 2024 was -25,962,451.61 RMB, compared to -27,835,471.27 RMB in Q1 2023, indicating a reduction in comprehensive loss of about 6.3%[19] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 13,863,768.33, indicating a positive cash flow despite the net loss[5] - Cash flow from operating activities generated a net inflow of 13,863,768.33 RMB in Q1 2024, a significant recovery from a net outflow of -27,687,230.10 RMB in Q1 2023[23] - Cash and cash equivalents as of March 31, 2024, amounted to ¥182,529,839.73, an increase from ¥172,259,633.41 as of December 31, 2023[13] - The cash and cash equivalents at the end of Q1 2024 stood at 182,529,839.73 RMB, an increase from 140,098,797.46 RMB at the end of Q1 2023, representing a growth of approximately 30.3%[24] - The cash flow from investing activities resulted in a net outflow of -2,181,622.15 RMB in Q1 2024, compared to -811,156.74 RMB in Q1 2023, indicating an increase in investment outflow[23] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 1,295,456,592.55, down 4.70% from the end of the previous year[6] - Total assets as of March 31, 2024, were ¥1,295,456,592.55, down from ¥1,359,312,015.51 at the end of 2023[16] - Total liabilities decreased to ¥54,101,286.53 from ¥91,994,257.88, a reduction of approximately 41%[15] - Shareholders' equity attributable to the listed company decreased by 2.13% to CNY 1,238,161,240.47 compared to the end of the previous year[6] Operational Metrics - Total operating revenue for Q1 2024 reached ¥84,499,399.27, a significant increase of 50% compared to ¥56,346,354.72 in Q1 2023[17] - Total operating costs for Q1 2024 were ¥108,529,464.19, up from ¥84,161,826.81 in Q1 2023, reflecting a 29% increase[17] - The company's gross profit margin decreased, with gross profit for Q1 2024 at ¥45,850,000.00, compared to ¥36,000,000.00 in Q1 2023[17] - The company incurred operating expenses of 71,094,754.38 RMB in Q1 2024, down from 76,852,343.62 RMB in Q1 2023, showing a decrease of approximately 7.5%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 61,429, with the largest shareholder holding 32.1% of the shares[10] Research and Development - The company reported R&D expenses of ¥1,191,317.83 for Q1 2024, a decrease from ¥2,036,313.84 in Q1 2023, reflecting a 41% reduction[17] Future Outlook - The company plans to continue expanding its product lines and market presence, focusing on innovative product development[8] - The management emphasized the importance of cash flow management in light of the current financial performance and market conditions[8] Non-Recurring Items - Non-recurring gains and losses amounted to CNY 80,061.31, with significant contributions from government subsidies and asset disposals[8] - The company reported investment income of 58,635.62 RMB in Q1 2024, compared to 38,652.91 RMB in Q1 2023, reflecting a growth of about 51.8%[23]